Notification That Annual Report Will Be Submitted Late (nt 10-k)
April 01 2022 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES |
OMB
APPROVAL |
SECURITIES
AND EXCHANGE COMMISSION |
OMB
Number: . . . . . . . . 3235-0058 |
Washington,
D.C. 20549 |
Expires:
. . . . . . . February 28, 2022
|
|
Estimated
average burden |
|
Hours
per form. . . . . . . . . . . . . . 2.50 |
FORM 12b-25 |
|
|
SEC
FILE NUMBER |
|
001-37685 |
|
|
NOTIFICATION OF LATE FILING |
CUSIP
NUMBER |
|
70387R
106
|
(Check One):
☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form
N-SAR ☐ Form N-CSR
For Period Ended: December
31, 2021
☐ Transition
Report on Form 10-K
☐ Transition
Report on Form 20-F
☐ Transition
Report on Form 11-K
☐ Transition
Report on Form 10-Q
☐ Transition
Report on Form N-SAR
For the Transition Period
Ended: ______________________
Read Instructions (on back
page) Before Preparing Form. Please Print or Type.
Nothing in this form shall
be construed to imply that the Commission has verified any information contained herein. |
If the notification relates to a portion of the filing
checked above, identify the Item(s) to which the notification relates:
N/A
PART I – REGISTRANT INFORMATION
PAVMED INC.
Full Name of Registrant
N/A
Former Name if Applicable
One Grand Central Place, Suite 4600
Address of Principal Executive Office (Street and Number)
New York, New York 10165
City, State and Zip Code
PART II – RULES 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
|
(a) |
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
☒ |
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|
(c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III – NARRATIVE
State below in reasonable detail the reasons why the
Forms 10-K, 20-F, 11-K, 10-Q, 10-D, NBSAR, N-CSR, or the transition report or
portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed)
The
Registrant was unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the fiscal year ended December
31, 2021, because the Registrant is still compiling information for the subject Form 10-K, specifically information for the footnotes
of the financial statements. It is anticipated the subject Form 10-K will be filed with the U.S. Securities and Exchange Commission within
the prescribed deadline.
PART IV – OTHER INFORMATION
(1) |
Name and telephone number of person to contact in regard to this notification |
Dennis M. McGrath |
|
(212) |
|
949-4319 |
(Name) |
|
(Area Code) |
|
(Telephone Number) |
(2) |
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). |
☒ Yes ☐ No |
|
|
(3) |
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? |
☒ Yes ☐ No |
|
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.
The
Registrant expects to report a net loss attributable to common stockholders of approximately $50.6 million for the fiscal year ended
December 31, 2021. This compares to a net loss attributable to common stockholders of approximately $34.6 million for the fiscal
year ended December 31, 2020.
|
PAVMED INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: April 1, 2022 |
By: |
/s/ Dennis M. McGrath |
|
|
Dennis M. McGrath,
President & Chief Financial Officer |
INSTRUCTION: The form may be signed by an executive
officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed
or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an
executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute
Federal Criminal Violations (See 18 U.S.C. 1001). |
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Sep 2024 to Oct 2024
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Oct 2023 to Oct 2024